Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitapivat in Transfusion-Dependent Alpha- or Beta-Thalassemia
NCT04770779Phase 3Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of mitapivat in alpha thalassemia, beta thalassemia, sponsored by Agios Pharmaceuticals. Started Nov 2021; status: active, not recruiting.
02
Drugs
mitapivat
03
Conditions
alpha thalassemiabeta thalassemia
Beyond the preview
Go deeper on NCT04770779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770779.